U-500 insulin: Why, when and how to use in clinical practice

Diabetes/Metabolism Research and Reviews

Volumn 23, Issue 4, 2007, Pages 265-268

  Garg, Ranjna ^a   Johnston, V ^a   McNally, P G ^a   Davies, M J ^a   Lawrence, I G ^a  

^a LEICESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Insulin resistance; Type 2 diabetes mellitus; U 500 insulin

Indexed keywords

GLITAZONE DERIVATIVE; GLUCOSE; INSULIN; INSULIN ASPART; INSULIN GLARGINE; INSULIN LISPRO; INSULIN SENSITIZING AGENT; ISOPHANE INSULIN; METFORMIN; NEUTRAL INSULIN; PIOGLITAZONE; ROSIGLITAZONE;

BLOOD GLUCOSE MONITORING; CLINICAL DECISION MAKING; CLINICAL PRACTICE; CONTINUOUS INFUSION; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG COST; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG INDICATION; DRUG INJECTION VOLUME; DRUG STORAGE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; GLYCEMIC CONTROL; HEALTH CARE ACCESS; HOSPITAL ADMISSION; HUMAN; INSULIN HYPOGLYCEMIA; INSULIN PUMP; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; MEDICATION ERROR; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PATIENT COMPLIANCE; PATIENT EDUCATION; PATIENT INFORMATION; PATIENT SAFETY; PATIENT SATISFACTION; PATIENT SELECTION; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TREATMENT DURATION; WEIGHT REDUCTION;

DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG COSTS; HOSPITALIZATION; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INJECTIONS; INSULIN; PROFESSIONAL PRACTICE; RISK ASSESSMENT;

EID: 34249797616     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.709     Document Type: Review

References (12)

1. Nathan DM, Axelrod L, Flier JS, et al. U-500 insulin in the treatment of antibody-mediated insulin resistance. Ann Intern Med 1981; 94: 653-656.
2. Baumann G, Drobny EC. Enhanced efficacy of U-500 insulin in the treatment of insulin resistance caused by target tissue insensitivity. Am J Med 1984; 76: 529-532.
3. Fain JA. Insulin resistance and the use of U-500 insulin: a case report. Diabetes Educ 1987; 13: 386-389.
4. Knee TS, Seidensticker DF, Walton JL, et al. A novel use of U-500 insulin for continuous subcutaneous insulin infusion in patients with insulin resistance: a case series. Endocr Pract 2003; 9: 181-186.
5. Garg R, Lawrence IG, Akinsola MO, et al. Improved glycaemic control in severely insulin resistant, insulin treated diabetic patients with U500 Human Actrapid over two year follow-up. Diabetologia 2004; 47(Suppl. 1): A58.
6. Cochran E, Musso C, Gorden P. The use of U-500 in patients with extreme insulin resistance. Diabetes Care 2005; 28: 1240-1244.
7. Neal JM. Analysis of effectiveness of human U-500 insulin in patients unresponsive to conventional insulin therapy. Endocr Pract 2005; 11(5): 305-307.
8. Lane WS. Use of U-500 regular insulin by continuous subcutaneous insulin infusion in patients with type 2 diabetes and severe insulin resistance. Endocr Pract 2006; 12(3): 251-256.
9. Wafa WS, Khan MI. Use of U-500 regular insulin in type 2 diabetes. Diabetes Care 2006; 29(9): 2175-2176.
10. Jorgensen KH, Hansen AK, Buschard K. Five fold increase of insulin concentration delays the absorption of subcutaneously injected human insulin suspensions in pigs. Diabetes Res Clin Pract 2000; 50: 161-167.
11. Garg R, Lawrence IG. PGMcNally and Davies MJ: improved glycaemic control with short term use of U-500 insulin in poorly controlled patients with type2 diabetes mellitus is maintained for up to 3.5 years with conventional insulin regimens: a prospective observational follow up study. Diabetes 2006; 55(Suppl.), Abstract 597-P.
12. Cohen MR. Drop that insulin syringe. Nursing 2002; 32(1): 18.